Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
Once injected (usually once weekly), they mimic the effects of GLP-1, helping your body better control blood sugar and manage hunger
doi: 10.1016/j.hrtlng.2005.04.002
Meanwhile, non-peptide alternatives are also making progress
(2022) Tirzepatide - a dual GIP/GLP-1 receptor agonist - a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes
Charge accordingly
It targets three key hormone receptors at the same time: GLP-1 (glucagon-like peptide-1) Stimulates insulin release Reduces glucagon secretion Helps regulate blood sugar GIP (glucose-dependent insulinotropic polypeptide) Enhances insulin response Improves insulin sensitivity Glucagon Receptors Increases energy expenditure Promotes satiety and appetite control This triagonist design offers a multifaceted attack on metabolic dysfunction, addressing blood sugar, appetite, and energy usage all at once
US$ 29.91
US$ 20.04
US$ 29.16
US$ 27.85
US$ 27.32
US$ 23.78
US$ 24.87
